| Document |
Document Title |
|
JP3549125B2 |
Corticoid 17,21-dicarboxylic esters and corticoid 17-carboxylic esters 21-carbonic esters of the formula I with A equal to CHOH and CHClm CH2, C=0, 9(11) double bond; Y equal to H, F, Cl; Z equal to H, F, methyl, R(1) equal to aryl, heta...
|
|
JP3535555B2 |
PURPOSE: To obtain compounds used for anti-inflammatory or the like with high efficiency by, after treating specific steroid derivatives with a methylating agent in the presence of a copper-based catalyst, hydrolyzing the formed 16α- me...
|
|
JP2004516303A |
The invention relates to nitrate active steroid and pharmaceutical formulation thereof for use as anti-inflammatory agent.
|
|
JP2004514649A |
Synovial CRH functions in a paracrine manner to induce the nuclear transcription factor NURR1, which is abundantly expressed in the inflammatory cells of both rheumatoid arthritis and psoriatic arthritis synovium. This induction is suppr...
|
|
JP2004512359A |
The invention relates to novel medicament compositions based on anticholinergics and corticosteroids, a method for the production thereof and the use thereof for treating respiratory conditions.
|
|
JP2004511445A |
A unit dose formulation comprises less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. Once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rhe...
|
|
JP2004504403A |
The present invention relates to a process for the preparation of a compound of formula (I) which comprises the following step: wherein step (a) comprises oxidation of a solution containing the compound of formula (II) wherein the soluti...
|
|
JP3492717B2 |
PURPOSE: To efficiently obtain the compd. useful for an intermediate of medicines or the like at high yield by bringing a compd. obtd. by oxidizing a specified compd. in the presence of water to solvolysis reaction in an acidic medium or...
|
|
JP3466645B2 |
PURPOSE: To obtain the compd. free from by-products at high yield by using specified halohydrin as a starting raw material and bringing this to react under specified conditions. CONSTITUTION: Halohydrin of formula I (X is chlorine or the...
|
|
JP2003530301A |
The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumor...
|
|
JP2003528137A |
The present invention features methods of inhibiting progestin activity in a cell or in a subject in need of such inhibition, and methods of treating or preventing progestin-dependent conditions in a subject in need of such treatment or ...
|
|
JP3445271B2 |
Compounds of formula (I), wherein R17 and R'17 are such that: either R17 and R'17 together form ketone, hydrazono, oxime or methylene, or R17 is hydroxyl, hydroxymethyl or acyloxy and R'17 is hydrogen, alkyl or optionally substitued alke...
|
|
JP3418428B2 |
PURPOSE: To provide the novel steroid compounds whose steroid skeleton is bound at carbon atom 17 to a spiromethylene ring having progestational activity and antiprogenstational activities, and useful as contraceptive medicines. CONSTITU...
|
|
JP2003517472A |
The invention concerns a 3-methylene steroid derivative having general formula (1) wherein R1 is H or together with R3 forms a beta-epoxide or R1 is absent if there is a 5-10 or 4-5 double bond; R2 is (C1-C5) alkyl or CF3; R3 is betaH, b...
|
|
JP2003510277A |
The present invention provides methods for treating inflammatory conditions, including but not limited to, inflammatory bowel disease (ulcerative colitis, Crohn's disease, and proctitis), other noninfectious, inflammatory conditions of t...
|
|
JP3378245B2 |
Angiostatic steroids for use in controlling neovascularization and ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids and methods for their use in treating neovascularization and ocular hypertensio...
|
|
JP3356525B2 |
The invention relates to the compounds (I): R = oxo or beta -OH and A and B represent a free or protected 3-keto- DELTA <4> or DELTA <1,4> residue, their preparation, their application to the preparation of the compounds (A): R3 is a hyd...
|
|
JP2002356425A |
To provide a nonsurgical treatment for treating anal fissure and/or hemorrhoid or other benign anal diseases. The single nifedipine which is a calcium channel inhibitor, or a selective combination thereof with bethanechol is topically ap...
|
|
JP2002356422A |
To provide a nonsurgical cure or treatment for treating anal fissure and/or hemorrhoid or other benign anal diseases. Bethanechol of a choline agonist is topically applied to the anus to treat the benign anal diseases, especially the ana...
|
|
JP3352095B2 |
Nifedipine, optionally in combination with bethanechol, is administered locally to the anus for the treatment of benign anal disorders, in particular anal fissures and haemorrhoids. The agents induce a reduction in the mean and resting p...
|
|
JP3349554B2 |
The invention relates to a new process for preparing the compounds of formula (I): in which the rings A and B represent a 3-keto- DELTA <4>-6-R3, optionally in a form protected in position 3, or 3-keto- DELTA <1,4>-6-R3, R is methyl or -...
|
|
JP2002322168A |
To provide pharmaceutical compounds which reduce undesirable effects occurred at the region where is apart from the target site.Pharmaceutical compounds represented by general formula (I) or their salts or solvates, which are effective i...
|
|
JP2002308776A |
To provide a medicinal composition useful in the therapy for human prostatic adenocarcinoma.The medical composition for treating human prostatic adenocarcinoma contains a 5-α-reductase inhibiting compound such as 17β-(N-t- butylcarboxy...
|
|
JP3328729B2 |
PCT No. PCT/FR92/00549 Sec. 371 Date May 25, 1994 Sec. 102(e) Date May 25, 1994 PCT Filed Jun. 18, 1992 PCT Pub. No. WO92/22300 PCT Pub. Date Dec. 23, 1992.The invention relates to the domain of medicinal chemistry. It concerns more part...
|
|
JP3328377B2 |
PURPOSE: To economically obtain the subject compd. showing therapeutic activity without producing by-products by a new method of inverting a specified starting compd. into a halohydrin, rearranging the halohydrin in the presence of an al...
|
|
JP2002527448A |
This invention provides 5 alpha -pregnane-3 beta , (20S), 21-triol, 20-O- beta -glucuronide and 5 alpha -pregnane-3 beta ,20R-diol, 20-O- beta -glucuronide and pharmaceutically acceptalbe salts thereof which are useful as progestational ...
|
|
JP2002527525A |
The invention relates to a basic granulate comprising (7 alpha ,17 alpha )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, characterized in that the said granulate comprises (7 alpha ,17 alpha )-17-hydroxy-7-methyl-19-nor-17-pr...
|
|
JP2002201199A |
To provide a process for efficiently preparing a pregnane derivative useful as an intermediate or the like for synthesizing squaramine from an easily available raw material in a short step.This process for the preparation of the 21-hydro...
|
|
JP3292928B2 |
The present invention relates to compounds of the formula: in which X1 and X2 correspond to H or F without distinction; R1 represents the following radicals: and R2 represents the radicals in the form of an R epimer, an S epimer, or a st...
|
|
JP2002155097A |
To convert a 6β-fluorosteroid into a corresponding pharmacologically active 6α-fluoro derivative without requiring vigorous reaction conditions.This method for isomerizing a 6β-fluoro derivative into a corresponding 6α-fluoro derivat...
|
|
JP3281954B2 |
PCT No. PCT/FR91/00888 Sec. 371 Date Aug. 14, 1992 Sec. 102(e) Date Aug. 14, 1992 PCT Filed Nov. 12, 1991 PCT Pub. No. WO92/08730 PCT Pub. Date May 29, 1992.A process for crystallizing a pharmaceutically active steroidal product, without...
|
|
JP2002506077A |
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17beta-hydroxys...
|
|
JP2002500616A |
6 alpha -Hydroxy-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-pip
erazinyl]-16 alpha -methylpregna-1,4,9(11)-triene-3,20-dione, 6 beta -hydroxy-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-pip
erazinyl]-16 alpha -methylpregna-1,4,9...
|
|
JP2001526233A |
Compositions of angiostatic agents for treating GLC1A glaucoma and methods for their use are disclosed.
|
|
JP2001525333A |
(57) [Summary] 16α, 17α-dialkylated steroids are prepared by reacting 16α-alkyl-17 (20) -enyl-20-silyl ether with an alkylating agent and an enol silyl ether cleavage agent in a suitable solvent. It was.
|
|
JP2001525807A |
This invention provides a method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5 alpha -pregnan-3 beta -ol-20-on...
|
|
JP2001523638A5 |
|
|
JP2001512425A |
The invention provides a method of targeting a drug to areas of hypoxic and/or ischemic tissue within the body in which the desired drug species is linked to a non-cytotoxic bioreductive carrier. Also provided by the invention are novel ...
|
|
JP2001510170A |
Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steriod are disclosed.
|
|
JP3181589B2 |
PCT No. PCT/EP91/02493 Sec. 371 Date Oct. 27, 1993 Sec. 102(e) Date Oct. 27, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11277 PCT Pub. Date Jul. 9, 1992Compounds of the general formula I (I) are described, in which x represents an ox...
|
|
JP3172522B2 |
In accordance with the present invention, specific binding assays are disclosed which utilize an chemiluminescent compound, i.e., moiety, which has increased stability in aqueous solution. The chemiluminescent moiety is an ester, thioest...
|
|
JP3172575B2 |
PURPOSE: To provide a compd. useful for production of a budesonide and desonide. CONSTITUTION: The compd. of formula I (R is H, a 1 to 8C acyl, etc.). For example, (11β.16α)-21-(acetyloxy)-11-(formyloxy-16,17-[(1-methyleth
ylidene)bis(...
|
|
JP2000309536A |
To obtain the subject composition useful for treating prostatic adenocarcinoma by including a specific steroid 5-α-reductase inhibiting compound and a carrier. This pharmaceutical composition is obtained by including (A) a steroid 5-α-...
|
|
JP2000513380A |
There are described therapeutically active compounds or salts or solvates thereof, hydrolysable in human or animal blood to compounds with reduced therapeutic activity. There is also described a method of identifying a compound capable o...
|
|
JP2000264899A |
To obtain a steroid external preparation having excellent dispersibility in a base and emulsion stability, useful for treating acute eczema, atopic dermatitis, infantile eczema, etc., by making the external preparation include a specific...
|
|
JP2000256390A |
To obtain a medicine composition useful for treating diseases related to estrogen and androgen by making the composition include a pharmacologically acceptable diluent, or the like, and a specific sex steroid activity inhibitor. This com...
|
|
JP2000509016A |
Disclosed are (i) compounds of a steroid, a beta-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous produc...
|
|
JP2000508333A |
The subject of the invention is the products of formula (I):in which either R1 represents halogen, hydroxyl, (C1-C8) alkyloxy or (C1-C12) acyloxy, and R2 represents halogen or hydrogen, or R1 and R2 form together a double bond, Z is chos...
|
|
JP3058710B2 |
The present invention is directed to a group of compounds which are haloethyl substituted steroidal enzyme inhibitors. These compounds are useful as aromatase, 19-hydroxylase, and aldosterone biosynthesis inhibitors.
|
|
JP3056770B2 |
Products of general formula (I): in which R1 denotes an aliphatic hydrocarbon radical, R2 and R3, which are identical or different, denote a hydrogen atom or an alkyl radical, G denotes a hydrocarbon group containing from one to eighteen...
|
